Riccardo was the founder of Okairos, an infectious disease genetic vaccine company.

The genetic vaccine platform developed by Okairos, successfully tested in over four thousand individuals, formed the basis of the neoantigen genetic vaccine platform currently being tested by Nouscom in human malignancies.

Riccardo led Okairos through its successful acquisition by GSK in 2013, and his intuition, leadership, and ability to rapidly identify emerging fields of key emerging scientific importance with untapped potential continue to inspire our work daily.